On Thursday, Artivion received an upgrade to its Relative Strength (RS) Rating, from 64 to 73.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they begin their biggest runs. See if Artivion can continue to show renewed price strength and hit that benchmark.
Artivion is working on a cup without handle with a 32.33 entry. See if the stock can clear the breakout price in heavy volume.
While sales growth fell last quarter from 4% to 2%, the bottom line grew 0%, up from -91% in the prior report.
Artivion holds the No. 35 rank among its peers in the Medical-Products industry group. Boston Scientific, Penumbra and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
